share_log

大行评级｜建银国际：上调信达生物目标价至54.3港元 维持“跑赢大市”评级

Bank Rating | CCB International: Raising Cinda Biotech's Target Price to HK$54.3 to Maintain “Outperform the Market” Rating

Gelonghui Finance ·  Mar 26 04:30

CCB International raised Cinda Biotech's target price from HK$54.2 to HK$54.3, maintaining the “outperforming the market” rating. It believes that its outlook is stable and has a good catalyst. The results for the full year and the second half of last year beat expectations. Based on stable biotechnology fundamentals, it is the bank's first choice in the healthcare and biotechnology sector in the mainland. The bank believes that its lung cancer drug Tyvyt has multiple treatment indications in the national medical insurance list, and there is no need to drastically lower the price. It believes that the company can maintain product sales growth this year, estimated at 23% year-on-year, while the driving force of other drugs will also increase, and the commercialization process will continue to advance, generally keeping its revenue forecast unchanged.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment